Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
AR

NYSE · ARGX

argenx SE

Healthcare · Biotechnology

$825.03

Up+$6.40 (+0.78%)

Updated Oct 10, 2026, 6:24 PM

SID Score

4.4/10

Composite research score

Smart Money

56/100

Neutral

Market cap
47.46B
P/E ratio
42.26
Dividend yield
0.00%
52-week range
$661.85 – $1,072.75
Volume
512.25K
Avg. volume
347.54K

Price performance · ARGX

ARGX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

ARGX closed at $825.03 after 21 trading sessions, down 16.19% for the selected period.

Last close
$825.03
Period change
-16.19%
Period low
$818.63
Period high
$995.77
Daily close
View OHLC price history
ARGX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$821.955$826.78$805.07$825.03512.25K
Oct 8, 2026$831.23$832.24$787.73$818.632.45M
Oct 7, 2026$932.08$942.685$921.72$928.44258.33K
Oct 6, 2026$922.39$942.35$909.945$930.52430.07K
Oct 5, 2026$920.825$923.31$903.50$912.87322.13K
Oct 2, 2026$926.86$928.96$912.96$919.21333.88K
Oct 1, 2026$957.215$972.38$935.24$936.00302.25K
Sep 30, 2026$970.08$970.27$952.27$958.91243.75K
Sep 29, 2026$965.05$974.245$956.25$970.66311.05K
Sep 28, 2026$954.76$977.01$954.76$972.25264.66K
Sep 25, 2026$965.23$967.7075$956.24$959.49264.38K
Sep 24, 2026$945.81$965.34$944.21$962.22323.72K
Sep 23, 2026$974.60$974.60$934.185$945.82426.48K
Sep 22, 2026$986.43$986.77$963.50$963.79304.47K
Sep 21, 2026$996.50$1,001.95$986.56$988.20231.65K
Sep 18, 2026$1,001.62$1,003.83$989.33$990.32244.02K
Sep 17, 2026$991.74$1,000.87$988.565$995.77245.9K
Sep 16, 2026$981.94$988.335$974.26$984.69200.56K
Sep 15, 2026$985.87$1,000.59$977.03$979.76235.3K
Sep 14, 2026$1,004.56$1,008.32$988.40$990.54198.6K
Sep 11, 2026$1,001.62$1,002.95$983.10$984.39181.88K

Latest ARGX news

The latest Smart Investors Daily articles mentioning ARGX.

Stock researchCompany · Overview

ARGX research

Overview

Company profile and research snapshot.

Company profile

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$967.36
Implied upside
—
Analysts
10
ARGX recent ratings
DateFirmRatingTarget
Sep 23, 2026ROTHSCHILD & CO REDBURNBuy—
Sep 22, 2026BNP PARIBASOutperform—
Sep 22, 2026TD COWENBuy—
Sep 21, 2026DAY BY DAYBuy—
Sep 14, 2026KBC SECURITIESBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patientsReal-world evidence from more than 1,100 U.S. MG patients indicates the value of treating earlier with VYVGART Long-term data reinforce VYVGART’s consistent safety and efficacy profile in CIDP, and Phase 4 switch data support the feasibility of a direct, one-week transition from IVIg Empasiprubart Phase 2 study results in MMN

Yahoo · Sep 24, 2026

argenx (ENXTBR:ARGX) Shares Moved, So What Is Drawing Attention Now?

argenx (ENXTBR:ARGX) drew fresh attention after its Extraordinary General Meeting confirmed Thomas M. Brakel and Khurem Farooq as new non-executive directors, prompting investors to reassess how board composition might influence longer term decision making. argenx shares trade at €835.8 after a modest pullback, with the 30-day share price return down 3.29%. The 90-day move is up 6.91%, and the year-to-date share price return is 15.47%, while the 1-year total shareholder return sits at 34.37%...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By